--- title: "From treatment to prevention! Roche launches clinical trial for Alzheimer's disease Brainshuttle therapy" type: "News" locale: "en" url: "https://longbridge.com/en/news/292708776.md" description: "Roche announced the key clinical trial PrevenTRON for the Alzheimer's antibody drug trontinemab. The trial aims to utilize Brainshuttle technology to delay disease progression before symptoms appear. The study will recruit 1,600 individuals with biological markers but no cognitive impairment, screened through blood tests, with plans to initiate subject recruitment later, marking a shift in Alzheimer's treatment towards the prevention stage" datetime: "2026-07-15T04:14:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292708776.md) - [en](https://longbridge.com/en/news/292708776.md) - [zh-HK](https://longbridge.com/zh-HK/news/292708776.md) generator: "portal-rs" --- # From treatment to prevention! Roche launches clinical trial for Alzheimer's disease Brainshuttle therapy According to Zhitong Finance APP, Roche (RHHBY.US) has announced a key clinical trial plan for its Alzheimer's antibody drug, hoping to demonstrate that the drug can delay disease progression before symptoms appear. As competition intensifies, this pharmaceutical giant is racing against Eli Lilly (LLY.US) and Eisai to advance Alzheimer's treatment from the "treatment" stage to the "prevention" stage. It is reported that the study, named PrevenTRON, aims to recruit 1,600 individuals who have biological markers of Alzheimer's disease but have not yet exhibited any cognitive impairment. The study will use Roche's experimental antibody drug trontinemab, which incorporates Brainshuttle technology designed to deliver more and more stable doses of the drug to the brain. Roche unveiled key details of this trial design at the Alzheimer's Association International Conference held in London on Tuesday, including plans to start recruiting participants later this year. The company plans to use blood tests to identify individuals with elevated plasma pTau217 levels. This biomarker can identify those who appear healthy but are at a higher risk of developing Alzheimer's symptoms in the coming years. Researchers state that using blood tests to screen high-risk populations will make preventive clinical trials more feasible and cost-effective compared to brain scans. The trial plan will track the time it takes for participants to show measurable cognitive decline. This plan reflects a broader shift in the field of Alzheimer's research, which is moving towards starting treatment years before patients exhibit memory problems. Roche believes its Brainshuttle technology can deliver more antibodies to the brain, thereby clearing the sticky amyloid plaques that begin to accumulate years before symptoms appear, potentially increasing the chances of delaying or even preventing dementia. Azad Bonni, head of Roche's neuroscience and rare disease business, stated, "We are entering a new phase in this field." He added that the company hopes these drugs can help patients avoid progressing to the symptomatic stage. However, Roche is not the only company pursuing this goal. Eli Lilly has been conducting preventive studies with its approved Alzheimer's drug Kisunla for about four years and is expected to be the first to announce results from a large preventive clinical trial using an approved anti-amyloid drug. Like Roche, Eli Lilly is also using blood tests to screen cognitively normal individuals at the highest risk, identifying them before symptoms appear. Carole Ho, president of Eli Lilly's neuroscience business, stated, "We can fully envision a future where patients can be identified through blood tests years before symptoms appear, and we can then intervene." This optimism is increasingly being recognized across the entire research field. Jessica Langbaum, senior director of Alzheimer's prevention and research at the Banner Alzheimer's Institute, stated that anti-amyloid drugs work better the earlier they are administered, making preventive studies like those conducted by Roche and Eli Lilly a natural next step. She said in an interview, "The earlier the treatment, the better the drug works." Laura Nisenbaum, Executive Director of Drug Development and Interim Chief Scientific Officer at the Alzheimer's Drug Discovery Foundation, stated that Roche's Brainshuttle technology is expected to enhance the effectiveness of this treatment strategy by delivering more drugs to the brain. Unlike setting a fixed trial deadline, Roche will adopt an event-driven research design, continuing the trial until a sufficient number of subjects exhibit measurable cognitive impairment. This design will allow Roche to determine whether trontinemab can delay the progression of Alzheimer's disease from the asymptomatic early stage to the first appearance of clinical symptoms ### Related Stocks - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [4523.JP](https://longbridge.com/en/quote/4523.JP.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md) ## Related News & Research - [Roche's Divarasib Outperforms Approved Rivals in Phase III Lung Cancer Trial](https://longbridge.com/en/news/302240828.md) - [Ionis Advances IgA Nephropathy Program With Positive Phase 3](https://longbridge.com/en/news/302915763.md) - [Vabysmo shows signs of recovery as Roche gears up for busy 2027](https://longbridge.com/en/news/302787438.md) - [Hansoh Pharma expands Roche partnership to develop cancer therapies](https://longbridge.com/en/news/302272981.md) - [China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion](https://longbridge.com/en/news/302303029.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**